Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

2 results

  • Active substance : sufentanil
  • Topics : Pain - Inflammation
Filter
Topic
  • Diseases and conditions (2)
  • Plus ...
    • Pain - Inflammation (2)
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
  • Population groups (1)
  • Plus ...
    • Paediatrics (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Medicine (1)
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Practice guidelines (1)
Manufacturer
  • inconnu (1)
Language
  • Français (2)
Active substance
  • acide niflumique (1)
  • alcool (1)
  • amoxicilline (1)
  • aspirine (1)
  • bicarbonate de sodium (1)
  • chlorpromazine (1)
  • felbinac (1)
  • fentanyl (1)
  • hydromorphone (1)
  • midazolam (1)
  • morphine (1)
  • oxycodone (1)
  • pentazocine (1)
  • phosphate (1)
  • piroxicam (1)
  • sodium (1)
  • sufentanil (2)
  • sulfate de morphine (1)
 More filter Other Filter Icon
Search Export

Practice guidelines and other guides - 1 result

  • Assessment and management of acute pain in paediatric outpatients aged between 1 month and 15 years

    Practice guidelines - Posted on 1/3/2000 - Mis à jour le 19/7/2006
    Download abstract
    Add to my selection

Drugs, devices and medical acts - 1 result

  • ZALVISO (sufentanil)

    Medicine - Posted on 25/4/2016 - Mis à jour le 12/6/2019
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq1mNtu2kAQhu95CstSeweOwZxamyih0CAlKiXQVr2xFnsclppdZw+E9Om7YKKQyhS6sBdIsIeZ8cy/3w72L1eL1FoC45iSwHYrF7YFJKIxJg+BPRn3yy37slPy52iJdpapdZVq1baiFHEe2OvZyhQQ4ZUfd7efQO0HZndKlk+nc4jEm3VS4LRyg/jsDmXrNZa/pDi2FiBmNA7sTIrNqOVzwVQUnSfKfvEMReA725Hd2Xno7Y77ztrYEVYlB3aLyEOhUSBaNiPJGBDRRQIeKHsuNJ1EYbXV9NrVmpYLzEfAqWQRDJGYDRld4hjiYk8o5aDlJHmK74EtUxBrJ4XGnXm04FrG0RytRvA4KA76Ss12xUqUL8pus+bWPa9Vq7erdS1XbCdVxeJRD+HkFam7TdcB4qg9MhVIlGMoM4hmwNRHs1RDygRKDRUJ8+5buRnyw+DxoBhizLMUPVfmPNNNFWJITQNTUDD3IOsnGDOFqVTl7C/7RKap859RT7YQMRTxmlFdKonYw5L+SDcRXUoErPZXVA9/YrXVIgZ+PrO/KSlG/1BOUxzpEk4xSAIXk9FgP+AMsuEacZgwc3D4jklMn/j5obNbZEPRZxtuFhrNWOyG1Xar4dbr2mfqp1LUnvunJxnNwFE4wvwUygxIQk/lixJpsakXiZpS56Y3ohFKYU93VNYkj5LlSzNnTPjmDlU+UWj0c2+sq5avEtjz/eZnoWkcB6911uOyCdgrcR6KvH/V7Y3D+8l1eNUdD771Ai4T1a8ggtP3aJF9zOfHN727XhCFDa9R995V+/m3xmYFjhXjgyysuQ23VvNOgMkRPXmt2WrrHRdWzKqZEBn/4DgzxMscqRpUEnb0tXJ5KHvHZfBcWVTgf1WRub8dRvqSvE/LoW8o9Gl+mx8vA11aHOpaTu3Et/u3HX+hD8EknFCH/GIxhv9B7/w3ymsbbizs4RtKmXOzaZmRwJSY6t3k9B+M1b7DVGFJnyk6fEkSvOdV0F5h+k7+GqpT8p31K6hO6Q+HcTTE
NWwp909myXZZsddm